• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect

    2/27/24 12:34:19 PM ET
    $BSX
    $DHR
    $KRTX
    $LLY
    Medical/Dental Instruments
    Health Care
    Industrial Machinery/Components
    Industrials
    Get the next $BSX alert in real time by email

    Hedge funds are steering clear of the booming artificial intelligence (AI) market and other technology stocks that have led the market rally over the past year. Instead, they are placing their bets on the healthcare sector, revealing a calculated move towards stability and value.

    According to the Goldman Sachs Hedge Funds Monitor, hedge funds are heavily favoring the healthcare sector, allocating to it over 600 basis points beyond the benchmark’s weight.

    In the S&P 500, the healthcare sector boasts a 12.8% weight, while tech nearly 30%. For the median hedge fund portfolio as of the end of Q4 2023, healthcare a weight of nearly 20%, while tech was underweighted by six percentage points to about 24%.

    Much of this overweight is likely due to the relatively underwhelming performance of healthcare stocks compared to technology, as well as their relative affordability.

    The Technology Select Sector SPDR Fund (NYSE:XLK) has surged by nearly 50% in the past year. In contrast, healthcare stocks, as tracked by the Health Care Select Sector SPDR Fund (NYSE:XLV), have only risen by 13.7% over the same period.

    From a valuation perspective, while the technology sector trades at about 28 times its forward 1-year earnings, health care is relatively cheaper at 19 times forward earnings.

    Delving deeper, hedge funds have placed their bets on a handful of conviction healthcare stocks. As of December, prominent names in their portfolios, include:

    • Eli Lilly & Company (NYSE:LLY)
    • Tenet Healthcare Corp. (NYSE:THC)
    • Karuna Therapeutics (NASDAQ:KRTX)
    • Boston Scientific Corp. (NYSE:BSX)
    • Danaher Corp (NYSE:DHR).

    8 Top-Performing Health Care Stocks

    Name ITMarket CapPrice Chg. % ↓ (YTD)
    Eli Lilly and Company$ 694.85B32.42%
    Catalent, Inc.$ 10.55B29.95%
    Viatris Inc.$ 15.99B23.08%
    Da Vita Inc.$ 11.10B20.87%
    Merck & Co., Inc.$ 326.83B18.30%
    GE HealthCare Technologies Inc.$ 10.55B18.04&
    Striker Corp. $ 41.56B18.04%
    HCA Health care$82.50B5.80%

    Now Read: Ticking Time Bomb: Over 85% Of Americans Fear National Debt Crisis Impact On Their Future

    Image: Shutterstock

    Get the next $BSX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BSX
    $DHR
    $KRTX
    $LLY

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    1/7/2026$1250.00Buy
    UBS
    Eli Lilly and Company
    $LLY
    12/16/2025$1230.00Neutral → Buy
    Daiwa Securities
    Eli Lilly and Company
    $LLY
    12/15/2025$951.00 → $1145.00Buy
    Goldman
    Eli Lilly and Company
    $LLY
    12/15/2025$1286.00 → $1268.00Buy
    BofA Securities
    Danaher Corporation
    $DHR
    12/9/2025$265.00Buy
    Goldman
    Danaher Corporation
    $DHR
    12/2/2025$270.00Overweight
    Morgan Stanley
    Eli Lilly and Company
    $LLY
    11/13/2025$1165.00Sector Outperform
    Scotiabank
    Eli Lilly and Company
    $LLY
    11/10/2025$1104.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $BSX
    $DHR
    $KRTX
    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: EVP & CIDO Rau Diogo was granted 4,599 shares, increasing direct ownership by 21% to 26,397 units (SEC Form 4)

    4/A - ELI LILLY & Co (0000059478) (Issuer)

    2/12/26 4:22:48 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Finance, & CAO Zakrowski Donald A was granted 584 shares, increasing direct ownership by 21% to 3,423 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:27:28 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP&Pres, LLY USA&Global Capab Yuffa Ilya was granted 4,163 shares, increasing direct ownership by 15% to 32,304 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:26:05 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BSX
    $DHR
    $KRTX
    $LLY
    SEC Filings

    View All

    SEC Form 10-K filed by Eli Lilly and Company

    10-K - ELI LILLY & Co (0000059478) (Filer)

    2/12/26 1:58:32 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenet Healthcare Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TENET HEALTHCARE CORP (0000070318) (Filer)

    2/11/26 6:47:05 AM ET
    $THC
    Hospital/Nursing Management
    Health Care

    Danaher Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - DANAHER CORP /DE/ (0000313616) (Filer)

    2/10/26 4:22:59 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $BSX
    $DHR
    $KRTX
    $LLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BSX
    $DHR
    $KRTX
    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    3/1/24 4:00:21 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $DHR
    $KRTX
    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on Eli Lilly with a new price target

    UBS resumed coverage of Eli Lilly with a rating of Buy and set a new price target of $1,250.00

    1/7/26 9:11:47 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Eli Lilly from Neutral to Buy and set a new price target of $1,230.00

    12/16/25 8:49:23 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman reiterated coverage on Eli Lilly with a new price target

    Goldman reiterated coverage of Eli Lilly with a rating of Buy and set a new price target of $1,145.00 from $951.00 previously

    12/15/25 10:37:03 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BSX
    $DHR
    $KRTX
    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Boston Scientific to participate in TD Cowen's 46th Annual Health Care Conference

    MARLBOROUGH, Mass., Feb. 13, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in TD Cowen's 46th Annual Health Care Conference on Tuesday, March 3, 2026. Mike Mahoney, chairman and chief executive officer, and Kenneth Stein, M.D., senior vice president and global chief medical officer, will participate in a 30-minute question-and-answer session with the host analyst at approximately 9:10 a.m. ET. A live webcast and replay of the session will be accessible at https://investors.bostonscientific.com. The replay will be available approximately one hou

    2/13/26 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Tenet Reports Strong Fourth Quarter and FY 2025 Results; Provides 2026 Financial Outlook

    Net income available to common shareholders in fourth quarter 2025 was $371 million, or $4.22 per diluted share Adjusted diluted earnings per share1 increased 36.6% to $4.70 in fourth quarter 2025 compared to $3.44 in fourth quarter 2024 Consolidated Adjusted EBITDA1 in fourth quarter 2025 increased 12.9% to $1.183 billion compared to fourth quarter 2024; Fourth quarter 2025 Adjusted EBITDA margin was 21.4% Fourth quarter 2025 Ambulatory Care Adjusted EBITDA of $580 million increased 9.4% over fourth quarter 2024 FY 2026 Adjusted EBITDA Outlook is expected to be in the range of $4.485 billion to $4.785 billion Tenet Healthcare Corporation (Tenet) (NYSE:THC) today announc

    2/11/26 6:45:00 AM ET
    $THC
    Hospital/Nursing Management
    Health Care

    $BSX
    $DHR
    $KRTX
    $LLY
    Financials

    Live finance-specific insights

    View All

    Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

    Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in

    2/4/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boston Scientific announces results for fourth quarter and full year 2025

    MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share (EPS), compared to $566 million or $0.38 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.70 a year ago.

    2/4/26 6:30:00 AM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Danaher Reports Fourth Quarter and Full Year 2025 Results

    WASHINGTON, Jan. 28, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025.  All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key Fourth Quarter 2025 Results Net earnings were $1.2 billion, or $1.66 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 4.0% to $2.23.Revenues increased 4.5% year-over-year to $6.8 billion and non-GAAP core revenue increased 2.5% year-over-year.Operating cash flow was $2.1 billion and non-GAAP free cash flow was $1.8 billion.Key Full Year 2025 Results Net earni

    1/28/26 6:00:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $BSX
    $DHR
    $KRTX
    $LLY
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ryder System, Inc. Elects Tammy Romo to Its Board of Directors

    The board of directors of Ryder System, Inc. (NYSE:R) today announces the appointment of Tammy Romo, 63, to its board, effective January 5, 2026. Romo will serve as a member of the Audit and Finance Committees. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219927656/en/Ryder appoints Tammy Romo to its board of directors, effective January 5, 2026. "The board nominated Tammy as a director for her impressive results-oriented leadership style, proven ability to provide strategic oversight in complex public company settings, and her deep transportation expertise," says Ryder Chairman and CEO Robert Sanchez. "Tammy's experience in

    12/19/25 6:55:00 AM ET
    $R
    $THC
    Rental/Leasing Companies
    Consumer Discretionary
    Hospital/Nursing Management
    Health Care

    CathVision Announces Appointment of Eric Thepaut as Independent Chairman of the Board and Releases ECGenius® System Version 3.5

    COPENHAGEN, Denmark, Dec. 10, 2025 /PRNewswire/ -- CathVision, a medical technology company dedicated to improving clinical outcomes in cardiac electrophysiology through high-fidelity signal acquisition and intelligent software, today announced two major milestones: the appointment of Eric Thepaut as independent Chairman of the Board, and the commercial release of Version 3.5 of the ECGenius® System. Eric Thepaut Appointed Independent Chairman of the Board Eric Thepaut joins CathVision following his recent retirement from Boston Scientific Corporation (NYSE:BSX), where he serv

    12/10/25 4:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $DHR
    $KRTX
    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tenet Healthcare Corporation

    SC 13G/A - TENET HEALTHCARE CORP (0000070318) (Subject)

    11/14/24 4:17:18 PM ET
    $THC
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tenet Healthcare Corporation

    SC 13G/A - TENET HEALTHCARE CORP (0000070318) (Subject)

    11/14/24 1:22:34 PM ET
    $THC
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by Tenet Healthcare Corporation

    SC 13G - TENET HEALTHCARE CORP (0000070318) (Subject)

    11/12/24 10:34:15 AM ET
    $THC
    Hospital/Nursing Management
    Health Care